The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...

Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.

BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...

More than that, my latest PET CT showed damage to the airways in my lungs from all those months of coughing and illness. The official name for this latest ailment is bronchiectasis, a condition in ...

The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...

Almost 200 species of NTM are known to us, some of which can lead to diseases such as bronchiectasis ... Results of prior lung function testing (spirometry, lung volumes, DLCO, ct.). Despite our best ...